

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Arathoon, <i>et al.</i>	Confirmation No.:	1353
Application. No.:	09/520,130	Art Unit:	1643
Filed:	March 7, 2000	Examiner:	Holleran, Anne L.
For:	METHOD FOR MAKING MULTISPECIFIC ANTIBODIES HAVING HETEROMULTIMERIC AND COMMON COMPONENTS	Attorney Docket No:	12279-481-999

TERMINAL DISCLAIMER

**Mail Stop AF**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Genentech, Inc. is the assignee of the entire right, title and interest in and to U.S. Patent Application No. 09/520,130 by virtue of an assignment from the inventors of U.S. Patent Application No. 09/070,416 to Genentech, Inc., recorded on **July 24, 1998** at Reel **009345**, Frame **0069**, which assignment also assigns all divisions, continuations, and continuations-in-part of the '416 application. U.S. Patent Application No. 09/520,130 is a continuation of U.S. Patent Application No. 09/070,416.

Genentech, Inc. hereby disclaims the terminal part of any patent granted on the '130 application, which would extend beyond the expiration date of U.S. Patent No. 7,183,076, which issued on February 27, 2007. Genentech, Inc. is also the assignee of the entire 100% right, title, and interest in and to U.S. Patent No. 7,183,076 by virtue of an assignment from the inventors of Application No. 09/070,166 to Genentech, Inc., recorded on **June 17, 1998** at Reel **009266**, Frame **0974**. Application No. 10/143,437, filed on May 10, 2002, now U.S. Patent No. 7,183,076, is a continuation of Application No. 09/863,693, filed on May 23, 2001, which is a continuation of U.S. Application No. 09/070,166, filed on April 30, 1998. The assignment that was recorded on **June 17, 1998** at Reel **009266**, Frame **0974** in connection with U.S. Patent Application No. 09/070,166 also assigns the invention and all continuations and divisionals thereof.

Genentech, Inc. hereby agrees that any patent so granted on U.S. Patent Application

No. 09/520,130 shall be enforceable only for and during such period that said patent is commonly owned with U.S. Patent No. 7,183,076.

Genentech, Inc. further agrees that this agreement is to run with any patent granted on U.S. Patent Application No. 09/520,130 and is to be binding upon the grantee, its successors, and assigns.

Genentech, Inc. does not disclaim any terminal part of any patent granted on U.S. Patent Application No. 09/520,130 prior to the expiration date of the full statutory term of U.S. Patent No. 7,183,076 in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of common ownership stated above.

The undersigned hereby confirms that she has reviewed the assignment and, to the best of her knowledge and belief, title is in the assignee seeking to take action in this matter and that she is empowered to act on behalf of Genentech, Inc.

The undersigned hereby declares that all statements made herein of her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this 15 day of December 2010.

**Genentech, Inc.**

By: Victoria L. Boyd  
Name: **Victoria L. Boyd**  
Reg. No. **43,510**  
Position: **Senior Patent Counsel**